Growth Factors & Signaling

CJC-1295 (DAC-GHRH Analogue)

For Research Use Only. Not for Human or Veterinary Use.

Overview

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1–29) engineered for a very long duration of action. It carries four stabilising amino-acid substitutions and, in its DAC form, a group that binds covalently to circulating albumin — extending its half-life to several days and giving sustained GHRH-receptor activation. A “no-DAC” version (often called Modified GRF 1-29) is shorter-acting. It is a research compound.

Chemical Profile

PropertyValue
CAS number863288-34-8 (with DAC)
ClassGHRH(1–29) analogue with Drug-Affinity-Complex (DAC) technology
BackboneModified GHRH(1–29): D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ substitutions + C-terminal Lys–DAC
Molecular weight (with DAC)≈ 3647 g/mol
Molecular weight (no-DAC / Mod GRF 1-29)≈ 3368 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
CJC-1295 at a glance
Class
GHRH analogue (DAC technology)
Originator
ConjuChem Biotechnologies
Research status
Phase 1/2 clinical research
Study route
Subcutaneous
Half-life
≈ 6–8 days (albumin-bound, DAC form)
Key feature
Sustained GH / IGF-1 elevation for days

Mechanism of Action

CJC-1295 activates the GHRH receptor on pituitary somatotrophs, driving GH synthesis and release in a GHRH-like way (via Gαs and cAMP). Two engineering ideas extend its life: four amino-acid substitutions make it resistant to the DPP-4 enzyme, and — in the DAC form — a maleimide group binds albumin so the molecule circulates for days rather than minutes.

ComponentDetail
Primary targetGHRH receptor (GHRH-R) on somatotrophs
G-protein couplingGαs → adenylyl cyclase → cAMP → PKA
DPP-4 resistanceFour stabilising substitutions in the GHRH(1–29) core
Albumin binding (DAC)Covalent binding extends circulating half-life to days
GH / IGF-1Sustained elevation with the natural pulsatile pattern preserved

Pharmacology

ParameterValue
Half-life (t½)≈ 6–8 days (DAC form); short (no-DAC form)
Bioavailability (SC)≈ 70–80%
Time to peak (Tmax)≈ 12–24 h (DAC form)
MetabolismProteolytic degradation
Route of administrationSubcutaneous
EliminationRenal (peptide fragments)

Research Evidence

Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.

Study typeResearch focusReference
Healthy-volunteer studySustained GH / IGF-1 over multiple daysTeichman SL, et al. (2006)
GHRH-analogue pharmacologyDAC albumin-binding half-life extensionConjuChem / GHRH literature
Somatotropic-axis researchGH pulsatility with long-acting GHRHGHRH-analogue literature

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Sustained GH/IGF-1 elevation over several dayshealthy-volunteer studyTeichman SL et al., 2006
DAC albumin binding extends half-life to ~6–8 dayspharmacokinetic studiesGHRH-analogue literature

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 1–2 mg per injection (DAC form), every 5–8 days, in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~2–4 weeks
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
Local tolerabilityMild injection-site reactions
HormonalNo significant prolactin or cortisol elevation (GHRH mechanism)
ImmunogenicityLow to moderate (DAC conjugate)
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Soluble
logP≈ −2.0 (hydrophilic)
pH (reconstituted)5.0–7.0
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

CJC-1295 is built by Fmoc solid-phase synthesis of the modified GHRH(1–29) sequence; the DAC form then has a maleimidopropionyl-linker group conjugated to a lysine side chain, which is what lets it bind albumin in vivo.

StepDetail
StrategyFmoc solid-phase peptide synthesis
ResinRink amide / Wang resin
Core modificationsD-Ala², Gln⁸, Ala¹⁵, Leu²⁷ substitutions
DAC conjugationMaleimide-linker group on a Lys side chain (DAC form)
CleavageTFA / TIPS / H₂O with scavengers
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. The DAC and no-DAC forms are distinguished by mass; confirm the modification.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, reversed-phase TFA/ACN gradientSingle main peak
ESI-MS (positive mode)Identity / massdiffers between the DAC and no-DAC forms
MALDI-TOFMass confirmationdiffers between the DAC and no-DAC forms
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: reversed-phase TFA/ACN gradient · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode (differs between the DAC and no-DAC forms). The DAC and no-DAC forms are distinguished by mass; confirm the modification.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: The DAC and no-DAC forms are distinguished by mass; confirm the modification.

Selected References

  • Teichman SL, et al. Prolonged stimulation of GH and IGF-1 secretion by a long-acting GHRH analogue (CJC-1295) in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006.
  • GHRH-analogue and DAC albumin-binding technology literature.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS; DAC and no-DAC forms available
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need CJC-1295 — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote